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Background: Recent non-randomized studies suggest that extended endoscopic mucosal
resection (EMR) is equally effective in removing large rectal adenomas as transanal endoscopic
microsurgery (TEM). If equally effective, EMR might be a more cost-effective approach as this
strategy does not require expensive equipment, general anesthesia and hospital admission.
Furthermore, EMR appears to be associated with fewer complications.
The aim of this study is to compare the cost-effectiveness and cost-utility of TEM and EMR for the
resection of large rectal adenomas.
Methods/design: Multicenter randomized trial among 15 hospitals in the Netherlands. Patients
with a rectal adenoma ≥ 3 cm, located between 1–15 cm ab ano, will be randomized to a TEM- or
EMR-treatment strategy. For TEM, patients will be treated under general anesthesia, adenomas will
be dissected en-bloc by a full-thickness excision, and patients will be admitted to the hospital. For
EMR, no or conscious sedation is used, lesions will be resected through the submucosal plane in a
piecemeal fashion, and patients will be discharged from the hospital. Residual adenoma that is visible
during the first surveillance endoscopy at 3 months will be removed endoscopically in both
treatment strategies and is considered as part of the primary treatment.
Primary outcome measure is the proportion of patients with recurrence after 3 months. Secondary
outcome measures are: 2) number of days not spent in hospital from initial treatment until 2 years
afterwards; 3) major and minor morbidity; 4) disease specific and general quality of life; 5) anorectal
function; 6) health care utilization and costs. A cost-effectiveness and cost-utility analysis of EMR
against TEM for large rectal adenomas will be performed from a societal perspective with
respectively the costs per recurrence free patient and the cost per quality adjusted life year as
outcome measures.
Based on comparable recurrence rates for TEM and EMR of 3.3% and considering an upper-limit
of 10% for EMR to be non-inferior (beta-error 0.2 and one-sided alpha-error 0.05), 89 patients are
needed per group.
Discussion: The TREND study is the first randomized trial evaluating whether TEM or EMR is
more cost-effective for the treatment of large rectal adenomas.
Trial registration number: (trialregister.nl) NTR1422
Background
Rectal cancer is a common disease in the Netherlands with
approximately 4,000 new cases and 2,000 deaths annu-
ally[1]. The incidence of rectal cancer increases with age,
male sex and obesity, without ethnic preference [2-4]. In
the pathogenesis, premalignant intraepithelial neoplasia
that is located in a rectal adenoma, precedes the occur-
rence of invasive rectal cancer[5,6]. Early endoscopic
detection and removal of rectal adenomas prevents the
development of rectal cancer and is therefore the most
reliable contributor to the 'cure' of this disease[7,8]. When
rectal adenomas become large, however, standard endo-
scopic therapies like simple loop polypectomy or one-step
endoscopic resection will be inadequate. Therefore, large
rectal adenomas must be removed either surgically or by
extended endoscopic mucosal resection (EMR)[9].
In 1984 a novel surgical approach for the resection of
large rectal adenomas has been introduced in Germany:
transanal endoscopic microsurgery (TEM)[10]. This pro-
cedure encompasses general anesthesia, the use of expen-
sive specialized equipment, a full-thickness rectal wall
excision and hospital admission[11,12]. Since its intro-
duction, many surgical practices (including the Nether-
lands) have adopted TEM as the new standard therapy for
large rectal adenomas[13,14]. Alongside the introduction
and refinement of TEM for rectal adenomas, advanced
endoscopic therapies like extended EMR have rapidly
evolved[15,16]. For extended EMR no sedation, no
sophisticated equipment and no hospital admission are
required as opposed to TEM[9]. Furthermore, only the
neoplastic mucosa is resected instead of the full-thickness
rectal wall, having a potential benefit of fewer complica-
tions.
Supporters of the TEM technique praise the excellent
exposure of the rectum and the minimal invasiveness, as
opposed to conventional surgical techniques [17-19].
Besides, recurrence rates after TEM appear to be lower
when compared to conventional surgical transanal exci-Page 2 of 10
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cacious in several retrospective and prospective case series
with reported recurrence rates of 0–19% and complica-
tion rates of 2–21% [21-41].
On the other hand, extended EMR has gained more and
more support in the last few years, mainly due to good
clinical results after EMR in the esophagus and stom-
ach[42,43]. Endoscopic mucosal resection has also been
described for the treatment of large colorectal adenomas,
revealing recurrence rates of 0–9% and complication rates
of only 0–9% [44-53]. In case adenomas can not be
removed completely during one EMR attempt, repeat
EMR for residual disease generally leads to an overall suc-
cess rate of 96–100%. Recently, the first prospective study
analyzing extended EMR for large rectal adenomas has
been described, revealing a recurrence rate of 8% and
complication rate of 8%[9]. In this study, all recurrences
were detected during the first control endoscopy after 3
months; repeat EMR of residual disease led to an overall
success rate of 98.4%.
Since the efficacy of extended EMR for large rectal adeno-
mas appears to be comparable to TEM, we started a pro-
spective registration of patients with large non-
pedunculated rectal adenomas who were treated by EMR
in the Academic Medical Center Amsterdam. Preliminary
results of this study were published in abstract form, dem-
onstrating that EMR is safe and effective for the resection
of large rectal adenomas having an overall success rate so
far of 100%[54].
Until now, TEM and EMR have never been formally com-
pared, and no such comparative studies have been regis-
tered at this moment. Although selection bias inevitably
exists in prospective and retrospective case series, the
results of these studies suggest that both TEM and EMR
have comparable recurrence rates. Even when recurrences
occur after TEM or EMR, most of these can successfully be
re-treated without the need for radical surgery. The litera-
ture furthermore suggests that EMR is associated with
fewer complications, reduced hospital admission, and no
general anesthesia is required for EMR, all of which are
favorable in both patients' and societal perspective. These
contrasts of the two procedures might well lead to differ-
ences in costs and quality of life. Therefore, we designed a
multicenter randomized trial to compare TEM and EMR
for the resection of large rectal adenomas. The main objec-
tive of this study will be a cost-effectiveness and cost-util-
ity analysis of these two procedures.
Methods/Design
Hypothesis
Transanal endoscopic microsurgery and extended EMR
are both effective treatments for large rectal adenomas
with comparable recurrence rates. However, EMR does
not require general/spinal anesthesia or hospital admis-
sion and may be associated with lower morbidity. There-
fore, EMR may improve quality of life and reduce health
care costs.
Objective
The main objective of the proposed randomized study is
to compare the cost-effectiveness and cost-utility of TEM
and EMR for the removal of large rectal adenomas. For a
cost-effectiveness and cost-utility analysis the following
study aims are taken into consideration:
▪ Comparison of recurrence rates after removal of large
rectal adenomas by TEM or EMR.
▪ Comparison of morbidity and mortality associated with
both procedures, by counting the number of patients with
complications and the number of days that patients are
alive, outside the hospital and without recurrence.
▪ Comparison of general and disease specific quality of life
of patients before and after treatment by TEM or EMR.
▪ Comparison of health care service costs, production loss,
and out-of-pocket expenses for TEM and EMR.
Design
This will be a multicenter randomized trial comparing
TEM and EMR in patients with large rectal adenomas with
respect to cost-effectiveness and safety (figure 1).
Randomization
Patient data are entered into a computerized database and
by means of an unchangeable computer generated
number patients will be randomized to undergo TEM or
EMR. Randomization will be stratified by whether
patients have a primary adenoma or residual/recurrent
disease after prior resection.
Blinding
Blinding of patients and physicians during treatment is
unfeasible, since the two treatment strategies are highly
different in nature and in associated care. Endoscopic fol-
low-up for recurrence, however, will be performed by
independent endoscopists who are blinded for treatment
strategy (see also primary outcome measure).
Study population
Patients are eligible for this trial when they meet the fol-
lowing inclusion criteria:
(1) Diagnosed with a large non-pedunculated rectal ade-
noma (sessile or flat) with a largest diameter of ≥ 3 cm
(estimated by an opened biopsy forceps of 8 mm or an
opened resection snare of 13, 20 or 30 mm).Page 3 of 10
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and ≤ 15 cm from the anal verge, respectively.
(3) Biopsies of the lesion, if taken, did not show invasion
of neoplastic tissue in the submucosal layer on his-
topathological evaluation; only lesions with intraepithe-
lial (low or high grade) or intramucosal neoplasia are
suitable for inclusion.
(4) During flexible video endoscopy there are no signs of
endoscopic suspicion for submucosal invasive cancer
(Kudo pit pattern type V; excavated/depressed type mor-
phology; fold convergence; or large smooth nodule > 1 cm
in a flat lesion)[55,56].
(5) In case of doubt, endoscopic ultrasonography (EUS)
of the rectal adenoma should exclude invasion into the
submucosal layer and exclude pathological lymphaden-
opathy (lymph nodes > 1 cm). When pathological lymph
nodes are present, fine needle aspiration will be per-
formed to exclude lymph node metastasis.
(6) If not performed already, total colonoscopy will be
done to detect and remove all synchronous colonic ade-
nomas or cancers first. Cecal intubation must be con-
firmed by identification of the appendiceal orifice and
ileocecal valve.
(7) The general health condition of the patient permits
general/spinal anesthesia (ASA-classification I-III).
(8) Absence of non-correctable coagulopathy (interna-
tional normalized ratio > 2, or platelet count < 90 × 109/l).
(9) Patient age of 18 years or older.
Participating centers
Fifteen Dutch hospitals of the TREND-study group,
including four academic and eleven non-academic cent-
ers, will enroll patients.
Intervention strategies
Transanal endoscopic microsurgery
TEM will be performed as described by Buess[12]. Under
general/spinal anesthesia a specialized TEM rectoscope of
12 or 20 cm in length (Wolf GmbH Knittlingen or Storz
GmbH Tuttlingen, Germany) is inserted within the rec-
tum to assure proper visualization of the lesion. The rec-
toscope is fixed to the operating table by a supporting
device, providing the opportunity to reposition the recto-
scope during ongoing surgery. The rectal cavity is insuf-
flated with CO2 by a combined endosurgical unit to
achieve constant distension for appropriate visualization
of the rectal adenoma. The combined endosurgical unit
further regulates irrigation and suction, thereby maintain-
ing a constant intra rectal pressure. With the use of a bin-
ocular stereoscopic eyepiece for three-dimensional view
(Wolf GmbH only) or a forward oblique telescope (Storz
GmbH) a magnified view is being created for visualiza-
tion of the lesion. With various instruments (multifunc-
tional TEM400 (Erbe Elektromedizin GmbH, Tubingen,
Germany), Ultracision harmonic scalpel (Ethicon Endo-
Surgery, Cincinnati, USA), needle diathermy, tissue han-
dling forceps, needle holder, suction probe, injection nee-
dle, clip applicator) the adenoma will be dissected by
means of an en-bloc full-thickness rectal wall excision until
the perirectal fat. Postoperatively, patients will preserve a
urinary catheter that will be removed at the first postoper-
ative day. Patients are admitted to the hospital in accord-
ance with current practice.
After 3 months a control flexible endoscopy will be per-
formed. If presumed residual disease is seen, biopsies will
be taken to confirm the presence of neoplasia by histol-
ogy. Hereafter, the residual adenomatous tissue will be
resected endoscopically by either EMR (if > 5 mm) or
argon plasma coagulation (APC) (if < 5 mm). Any inter-
vention by EMR/APC at 3 months is part of the TEM treat-
ment strategy.
Endoscopic mucosal resection
Endoscopic mucosal resection is performed as described
by Karita and Hurlstone[9,15]. At the discretion of the
endoscopist, conscious sedation is used with 2.5–10 mg
midazolam and/or 25–100 μg of fentanyl. An endoscope
Flow chart of TREND study; 15 Dutch centers will be partic-ipating in his multicenter randomized trial (R = randomiza-ti n)igure 1
Flow chart of TREND study; 15 Dutch centers will be 
participating in this multicenter randomized trial (R 
= randomization).
Fulfilling inclusion criteria + informed consent (n=184) 
www.trend-studie.nl
EMR + 1st control (n=92) TEM + 1st control (n=92) 
Follow up (n=89): 
Endoscopies at 6, 12, 24 months 
Follow up (n=89): 
Endoscopies at 6, 12, 24 months
Patients evaluable for outcome (n=178):  
Recurrence rates, complications, quality of life and health care related costs 
Late exclusion due to submucosal 
invasive cancer ~3% 
Patients with large rectal adenomas 
RPage 4 of 10
(page number not for citation purposes)
BMC Surgery 2009, 9:4 http://www.biomedcentral.com/1471-2482/9/4(gastroscope or sigmoidoscope) is inserted into the rec-
tum and air insufflation via the endoscope will provide
proper distension of the rectum. The submucosa under-
neath the lesion will be injected through an endoscopic
injection catheter with a solution of saline 0.9%, 1 ml
methylene blue, and 1:10,000 units adrenaline in order to
lift the adenoma (no upper volume limit). A (barbed or
standard) resection snare will be placed around a part of
the lesion and subsequently tightened for resection
through the submucosal layer by electro-coagulation.
Each part of the adenoma will be resected by this piece-
meal fashion until the entire lesion is macroscopically
removed and the blue colored submucosa is visualized.
Visible submucosal vessels will be treated by endoscopic
clips or electro-coagulation to prevent delayed bleeding.
Hereafter, the edges of the mucosal defect and potential
remnants within the resection crater will always be treated
with APC to increase adenoma clearance. If bleeding dur-
ing the procedure precludes 100% clearance of the ade-
noma, the EMR procedure will be continued after 1 day
until all adenomatous tissue is resected. In case of proce-
dural blood loss of > 100 mL or if delayed perforation is
anticipated on procedural grounds, patients are admitted
to the hospital for observation; otherwise, they are dis-
charged after the procedure in accordance with current
practice.
After 3 months the treating endoscopist will perform a
control endoscopy. If presumed residual disease is seen,
biopsies will be taken to confirm the presence of neopla-
sia by histology. Hereafter, the residual adenomatous tis-
sue will be resected endoscopically by either EMR (if > 5
mm) or APC (if < 5 mm). Any intervention by EMR/APC
at 3 months is part of the EMR treatment strategy.
Informed consent procedure
Consecutive eligible patients will be recruited at the out-
patient clinic in the participating centers by the involved
physician (surgeon or gastroenterologist). Patients fulfill-
ing the abovementioned inclusion criteria will be
informed about the study by the physician. After written
informed consent, patients will be allocated to either TEM
or EMR by computerized block randomization with vari-
able block size via the study website http://www.trend-
studie.nl. The patient will subsequently be scheduled for
therapy in the participating centre. Patients unable or
refusing to provide informed consent will be treated
according to current clinical practice.
Intervention failure
When for technical reasons EMR procedures turn out not
to be performable after randomization, the patient will
automatically undergo the TEM treatment strategy. When
TEM turns out not to be performable, an attempt with
EMR will be done as well. When adenomas turn out to be
too large or too high in the rectum for TEM by the Storz
equipment, the patient will undergo TEM in another hos-
pital where Wolf equipment is available.
Safety monitoring
In order to control for quality of the treatment (TEM or
EMR) all procedures will be taped for reference. The first 3
procedures and an additional random sample per special-
ist will be assessed for quality by an expert panel at 2 time
points during each year.
Histopathological evaluation
Resection specimens after TEM will be stretched and
pinned on a cork plate before immersion into formalin.
After standard processing the resection specimen will be
transected each cm for evaluation by a gastrointestinal
pathologist. The lateral and basal resection margins will
be evaluated for absence of neoplasia, when possible. All
resected pieces by EMR will be processed in the same man-
ner, and only the basal resection margins will be evalu-
ated.
The risk of lymph node metastases is increased in case of
neoplasia extending into the submucosal layer, poor
tumor differentiation, mucinous cancer, vascular invasion
and tumor budding, all of which warrant further radical
surgery [57-60]. By strict adherence to the inclusion crite-
ria, the risk of invasive cancer is reduced to 1.6–
3%[56,61]. In case of an unexpected invasive cancer
despite adherence to the inclusion criteria, the patient will
be excluded after the histopathological evaluation (late
exclusion). In case of intramucosal cancer (i.e. not invad-
ing through the muscularis mucosae), both TEM and EMR
will be regarded as sufficient treatment when the lesion is
radically removed.
Outcome parameters
Primary outcome measure (for non-inferiority)
(1) Recurrence of neoplasia, defined as the presence of
histologically proven neoplastic tissue in either visible
recurrent lesions or in random biopsies, taken at surveil-
lance endoscopies after the intervention strategy has been
completed.
Any remnant adenoma identified and treated by EMR/
APC at 3 months is considered part of the initial interven-
tion strategy in both arms. Hereafter, patients will
undergo surveillance endoscopies (with a GIF-Q160
endoscope) at 6, 12 and 24 months by an independent
endoscopist who is blinded for the primary treatment.
During each surveillance endoscopy recurrence will objec-
tively be defined by the Higaki criteria for recurrence:
tumor appearing within a clear resection scar; tumors with
convergent folds; and tumors nearby a clear resection scar
(within 5 mm)[49]. Targeted biopsies will be taken forPage 5 of 10
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normal scar without evidence of recurrence, 3 biopsies
will be taken from the basis and 3 from the edges of the
scar to detect occult recurrent neoplasia.
(2) Since equal recurrence rates for the TEM and EMR
strategies are anticipated (equivalence trial), an additional
outcome measure has been chosen that is responsive to
both differences in initial care and to additional proce-
dures that may be required in both strategies: the number
of days that a patient is alive, outside the hospital and free
of recurrence during two-year follow-up starting at the day
of the initial treatment. Every patient therefore has poten-
tially 730 days, and hospital days will be subtracted for
initial treatment, readmissions, re-interventions and sur-
veillance endoscopies. Adenoma recurrence or death will
be considered as failure of the treatment strategy and no
more additional days outside the hospital will be counted
for such a patient.
'Unrelated' readmissions may have a relatively large
impact on the number of days outside the hospital as well
as on costs in this equivalence trial, if by chance they are
unevenly distributed among treatment arms. Therefore,
we will exclude the unrelated readmissions in a subse-
quent sensitivity analysis (both clinically and during the
cost-effectiveness and cost-utility analyses), meaning that
days in hospital due to clearly unrelated causes will not be
subtracted from the total number of potential days out-
side the hospital for a patient. Likewise, other unrelated
health care or unrelated days of sick leave will be excluded
in this sensitivity analysis. Whether readmissions are
related or unrelated to the target condition will be
assessed by an independent expert panel (blinded for
treatment).
The following standardized discharge criteria will be
applied in all participating hospitals: normal intake of
nutrition; normal mobility; absence of fever (< 38°C);
and stable hemoglobin level during 1 day (< 1 mmol/L)
in case of rectal blood loss.
Additional outcome measures
(a) Complications: subdivided into procedural (during
treatment) and delayed complications (after ending the
procedure); and further subdivided into major (requiring
additional surgery) and minor (requiring endoscopic or
medical intervention) complications.
During admission patients will be monitored for compli-
cations. In case of same day discharge from the hospital
patients will be called by telephone 1 day after the proce-
dure whether adverse events have happened. Two weeks
after the intervention, a research nurse will contact the
patient by telephone again and ask for occurred complica-
tions.
(b) Generic and disease-specific health related quality of
life will be measured at baseline, 2 weeks, 3 months, 6
months, 1 year and 2 year follow-up by the EQ-5D, SF-36,
Wexner score (for incontinence) and COREFO question-
naires[62].
(c) Costs of TEM and EMR from a societal perspective,
based on primary data (see economic evaluation section).
(d) Patient preferences regarding TEM or EMR will be
measured at the end of follow-up by a structured ques-
tionnaire to enable a discrete choice experiment address-
ing the burden of care, burden of complications,
prognostic uncertainties, and recurrence rates of both
treatments.
Sample size calculation
Assuming a baseline recurrence rate of 3.3% for both TEM
and EMR (average recurrence based on a systematic
review) and considering an upper limit of 10% for EMR to
be non-inferior, with a β-error of 0.2 and α-error of 0.05,
89 patients are needed per randomization group. As unex-
pected invasive cancers are expected in maximally 3% of
patients, the total sample size will be 184 patients.
Since EMR is known to be effective in even more than 2
attempts, an upper limit of 10% seems reasonable,
whereas higher recurrence rates would lead to many addi-
tional procedures which renders this strategy impractica-
ble and probably not cost-effective.
Ethics
This study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. The medical ethical committee of the Aca-
demic Medical Centre Amsterdam has approved the study
protocol (MEC number 08/183 # 08.17.1104). Prior to
randomization, written informed consent will be
obtained from all patients.
Data-analysis
Since the main outcome of this study is the neoplasia
recurrence rate, i.e. proportion of patients with recurrent
disease, the Chi-square test will be used to compare the
intervention groups (TEM versus EMR). Since the event of
recurrence, and not time to recurrence, is the most impor-
tant indicator for treatment failure, Kaplan Meier methods
will not be used. The complication and mortality rates
will be compared in the same manner. The number of
days not spent in hospital as additional primary outcome
measure will be compared by the Wilcoxon rank sum test.Page 6 of 10
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ous outcome measures (e.g. Wexner incontinence scale,
quality of life questionnaires) will be tested by the stu-
dent's t-test or Wilcoxon rank sum test, where appropriate.




The economic evaluation of EMR against TEM for large
rectal adenomas will be performed as a cost-effectiveness
analysis as well as a cost-utility analysis from a societal
perspective. The primary outcomes are the costs per recur-
rence free patient and the costs per quality adjusted life
year respectively. The costs per patient free of complica-
tions as well as the costs per day alive and outside the hos-
pital will be considered as secondary outcome. The time
horizon is restricted to a follow-up of 24 months. Given
this time span, discounting (of costs and effects) will be
performed. Incremental cost-effectiveness ratios are calcu-
lated, reflecting the extra costs per additional recurrence
free patient and the extra costs per additional QALY. Sen-
sitivity analyses will be performed to account for sampling
variability (following bias corrected and accelerated non-
parametric bootstrapping), for plausible ranges in unit
costs of surgery and endoscopic treatment, for (differen-
tial) discount rates of costs and effects, and for different
health utility algorithms (see below). Subgroup analyses
will be performed for patients with different rectal ade-
noma diameters (< 5 cm, 5–10 cm, > 10 cm) and dis-
tances of the adenoma from the anal verge (< 7.5 cm
versus 7.5–15 cm) in order to tentatively assess differences
in health care efficiency.
In case TEM and EMR turn out clinically equivalent, the
study will be performed as a cost-minimization analy-
sis[63].
Cost analysis
The evaluation will include the direct medical costs, out-
of-pocket expenses, and the indirect non-medical costs of
production loss. The direct medical costs will include the
costs of all diagnostic procedures (except study-related
ones like anal manometry), therapeutic (repeat) interven-
tions, medication, admissions, day care treatments, spe-
cialist consultations, and out-of-hospital care (like general
physician, fecal incontinence pads, etc) during follow-up.
With approximately over 40% of patients below 65 years
of age, production losses will be estimated and based on
questionnaire data concerning absence from work and
lower efficiency while at work. Out-of-pocket expenses
will include the costs of health-related travel, over-the-
counter medication, extra washing, etc. Volume data will
be gathered with clinical report forms, available hospital
information systems, and the Dutch Health and Labour
Questionnaire (to be completed by patients at baseline,
week 2, and months 3, 12, and 24). The Dutch costing
guideline for health care research will be used to deter-
mine the relevant unit costs. In case of the TEM and EMR
however, micro-costing (general/spinal/conscious
anesthesia or sedation, surgical and endoscopic equip-
ment, procedure duration, involved personnel, overhead)
in participating centers will be done to estimate real unit
costs. The friction costs method will be applied to derive
the costs of lost productivity. After price-indexing all costs
will be expressed in 2009 euros.
Patient outcome analysis
Patients' health status and quality of life will be assessed
with the Wexner score, COREFO and SF-36. In addition,
the EQ-5D questionnaire is used to generate health status
scoring profiles over time, which will subsequently be
translated in QALYs by applying time trade-off based
health utility algorithms [64,65] (see also the sensitivity
analyses above) and assuming that a health utility score at
any point in time best reflects a patients health status in-
between the actual and the previous measurement. In
addition, patient preferences regarding TEM and EMR will
be measured at the end of follow-up by a structured ques-
tionnaire to enable a discrete choice experiment address-
ing the burden of care, burden of complications,
prognostic uncertainties, and recurrence rates of both
treatments[66].
Discussion
Colorectal cancer (CRC) is the second most common can-
cer in the Netherlands with 9,989 new cases and 4,429
deaths in the year 2003[1]. Rectal cancer accounts for
approximately 40% of those CRC cases. The treatment of
rectal cancer encompasses a multidisciplinary collabora-
tion including gastroenterologists, surgeons, oncologists,
radiotherapists and specialized nurse practitioners. Stand-
ard therapy consists of radical surgery in combination
with radiotherapy (and possibly chemotherapy), which
have major morbidity and mortality[67]. Therefore, this
disease has a major impact on health care services[68].
Since early detection and removal of rectal adenomas pre-
vents the occurrence of rectal cancer, CRC screening has
been adopted in many western countries[69]. In the Neth-
erlands a pilot study for CRC screening, based on fecal
occult blood testing, has been performed (ZonMw
funded)[70]. When CRC screening is introduced in the
Netherlands, this will inevitably lead to an increased
detection of early rectal neoplasia[71]. It is therefore
expected that more rectal adenomas will need endoscopic
or surgical treatment in the forthcoming years. Conse-
quently, the most appropriate therapy concerning effi-
cacy, safety, quality of life and costs must be selected to
deal with the expected increase in rectal adenomas.Page 7 of 10
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not be resected endoscopically were referred for surgery.
Conventional surgical approaches like radical surgery and
trans-sphincteric or trans-sacral operations have nowa-
days been replaced by TEM, since this procedure has
higher efficacy and lower morbidity [18-20]. However, no
improvement in quality of life could be encountered by
TEM, when compared to conventional radical sur-
gery[17]. In recent years endoscopic therapies have further
evolved, as a result of which large rectal adenomas more
often are treated endoscopically, at the expense of TEM[9].
In case series, endoscopic resection of large colorectal ade-
nomas has led to recurrence rates that were comparable to
TEM (2.0% vs. 3.6% respectively), and complication rates
that appeared lower (4.4% vs. 10.7%)[9,22,23,26,27,29-
31,34-37,41,45,48,49,52,53,72-74]. Furthermore, EMR
can safely be performed without sedation, or with con-
scious sedation only, and generally no hospital admission
is required as opposed to TEM. The reduced morbidity,
reduced hospital admission and redundancy of anesthesia
associated with EMR are beneficial from both patients'
and societal perspective.
Nevertheless, current clinical practice concerning the
treatment of large rectal adenomas mainly depends on
experience with TEM or EMR in various hospitals and on
the clinical judgment of the involved physician instead of
on evidence, which is lacking with reference to the treat-
ment of large rectal adenomas. Although the literature
suggests that TEM and EMR are equivalent techniques
concerning efficacy and that EMR appears favorable con-
cerning morbidity, a formal comparison of cost-effective-
ness and cost-utility has never been performed and no
ongoing studies comparing these two techniques have
been registered in trial-registers so far.
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